tacrine has been researched along with curcumin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Manral, A; Maqbool, M; Saini, V; Shandilya, A; Tiwari, M | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Cen, J; Chen, Y; Hong, C; Luo, W; Wang, CJ; Wang, T; Xie, SQ; Yang, YC | 1 |
| Kong, LY; Li, F; Li, XM; Wang, J; Wang, XB; Wang, ZM; Wu, JJ | 1 |
| Cai, P; Kong, LY; Liu, QH; Wang, XB; Wang, ZM; Wu, JJ; Xu, DQ; Yang, XL | 1 |
| Chen, W; Huangli, Y; Qin, J; Shen, Y; Tang, H; Wang, L; Wei, S | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Ahmed, W; Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mumtazuddin, S; Tiwari, M | 1 |
| Du, H; Ma, F | 1 |
| Cen, J; Fang, D; Guo, H; Hong, C; Luo, W; Lv, J; Wang, C; Wang, T; Yang, Y | 1 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Kay, G; Kong Thoo Lin, P; Megson, IL; Scipioni, M | 1 |
| Ji, J; Peng, Y; Rakesh, KP; Wang, S; Xu, M; Zhu, L | 1 |
| Chen, YP; Guo, HY; Luo, W; Lv, JW; Ma, J; Song, ZY; Wang, CJ; Wang, T; Zhang, ZY | 1 |
| Du, H; Jiang, X; Liu, S; Ma, F; Ma, M; Xu, H | 1 |
| Asawa, Y; Bajorath, J; Ban, HS; Nakamura, H; Okada, S; Yoshimori, A; Yudi Utomo, R | 1 |
| Ju, H; Kou, X; Shen, R; Wu, J; Yang, A; Zhang, H | 1 |
| Chen, S; Du, J; Li, R; Li, Z; Liu, T; Xing, S | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Chen, L; Lei, Z; Sun, J; Sun, X; Wang, Y; Yue, S | 1 |
| Hitge, R; Petzer, A; Petzer, JP | 1 |
| Albuquerque, HMT; Malafaia, D; Silva, AMS | 1 |
| Chung, KH; Kim, CH; Ko, JH; Koo, BS; Lee, WC | 1 |
3 review(s) available for tacrine and curcumin
| Article | Year |
|---|---|
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Triazoles | 2019 |
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Curcumin; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Structure-Activity Relationship; Tacrine; tau Proteins | 2021 |
20 other study(ies) available for tacrine and curcumin
| Article | Year |
|---|---|
Development of cyanopyridine-triazine hybrids as lead multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Molecular Targeted Therapy; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Pyridines; Triazines | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Design, synthesis and evaluation of 4-dimethylamine flavonoid derivatives as potential multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Death; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Dimethylamines; Drug Design; Flavonoids; Humans; Hydrogen Peroxide; Intracellular Space; Kinetics; Molecular Docking Simulation; PC12 Cells; Peptide Fragments; Protein Aggregates; Protein Conformation; Rats; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Electrophorus; Horses; Humans; Indans; Indoles; Iron; Kinetics; Melatonin; Molecular Docking Simulation; Peptide Fragments; Piperidines; Protein Multimerization; Rats; Zinc | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Copper; Donepezil; Drug Design; Humans; Indans; Kinetics; Liver; Mice; Models, Molecular; Peptide Fragments; Piperidines; Protein Aggregates; Protein Conformation | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Protein Aggregates; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Triazines | 2017 |
Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Ligands; Molecular Structure; Peptide Fragments; Protein Aggregates; Quinazolines; Structure-Activity Relationship | 2017 |
Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Biphenyl Compounds; Cell Line; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Cholinesterases; Cognition; Drug Design; Hep G2 Cells; Humans; Liver; Male; Mice, Inbred ICR; PC12 Cells; Rats; Tacrine | 2018 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Synthesis of novel vanillin derivatives: novel multi-targeted scaffold ligands against Alzheimer's disease.
Topics: | 2019 |
Synthesis, in vitro and in vivo biological evaluation of novel graveolinine derivatives as potential anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Hep G2 Cells; Horses; Humans; Male; Methoxsalen; Mice; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Development of curcumin-based amyloid β aggregation inhibitors for Alzheimer's disease using the SAR matrix approach.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesterase Inhibitors; Curcumin; Dose-Response Relationship, Drug; Drug Development; Humans; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Structure-Activity Relationship | 2021 |
Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carbamates; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Electrophorus; Flavanones; Free Radical Scavengers; Horses; Kinetics; Molecular Docking Simulation; Molecular Structure; Peptide Fragments; Protein Binding; Protein Multimerization; Structure-Activity Relationship | 2021 |
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Biphenyl Compounds; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Oxadiazoles; Picrates; Protein Aggregates; Structure-Activity Relationship | 2022 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Rats | 2022 |
Isatoic anhydrides as novel inhibitors of monoamine oxidase.
Topics: Acetylcholinesterase; Amines; Amino Acids; Anhydrides; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Isoforms; Quinolones; Structure-Activity Relationship | 2022 |
A water extract of Curcuma longa L. (Zingiberaceae) rescues PC12 cell death caused by pyrogallol or hypoxia/reoxygenation and attenuates hydrogen peroxide induced injury in PC12 cells.
Topics: Animals; Caspase Inhibitors; Catalase; Cell Death; Cell Hypoxia; Cell Survival; Curcuma; Enzyme Inhibitors; Free Radical Scavengers; Glutathione Peroxidase; Hydrogen Peroxide; L-Lactate Dehydrogenase; Malondialdehyde; Microscopy, Electron; Oxidative Stress; PC12 Cells; Plant Extracts; Pyrogallol; Rats; Reactive Oxygen Species; Superoxides; Tacrine | 2004 |